Familial Mediterranean fever and growth: Effect of disease severity and colchicine treatment

被引:0
作者
Zung, A [1 ]
Barash, G
Zadik, Z
Barash, J
机构
[1] Hebrew Univ Jerusalem, Pediat Endocrinol Unit, Kaplan Med Ctr, Hadassah Med Sch, IL-76100 Rehovot, Israel
[2] Hebrew Univ Jerusalem, Rheumatol Unit, Kaplan Med Ctr, Hadassah Med Sch, IL-76100 Rehovot, Israel
关键词
familial Mediterranean fever; colchicine; growth;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To evaluate the effect of disease severity and colchicine treatment on height and weight parameters in children with familial Mediterranean fever (FMF). Methods: Thirty prepubertal children (19 M, 11 F) were studied retrospectively. Z-score values of height, growth velocity, weight and body mass index were obtained over 1.84 +/- 1.14 years before and 2.58 +/- 1.55 years during colchicine therapy. Disease severity was evaluated by a specific score for FMF. Results: By comparison to growth before treatment, during colchicine therapy height SDS increased from -1.00 +/- 1.17 to -0.54 +/- 0.96 (p < 0.001) and weight SDS increased from -0.74 +/- 1.09 to -0.47 +/- 1.06 (p = 0.008). An effect of disease severity on growth pattern could not be detected. Height SDS during therapy was negatively correlated with age at colchicine initiation. Conclusions: Colchicine therapy has a positive effect on both height and weight parameters in children with FMF. Early initiation of treatment is beneficial for height gain.
引用
收藏
页码:155 / 160
页数:6
相关论文
共 21 条
  • [1] Aksentijevich I, 1997, CELL, V90, P797
  • [2] Andersen E, 1982, Ugeskr Laeger, V144, P1760
  • [3] BODY-MASS INDEX REFERENCE CURVES FOR THE UK, 1990
    COLE, TJ
    FREEMAN, JV
    PREECE, MA
    [J]. ARCHIVES OF DISEASE IN CHILDHOOD, 1995, 73 (01) : 25 - 29
  • [4] Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I - A model for stunted growth in children with chronic inflammation
    DeBenedetti, F
    Alonzi, T
    Moretta, A
    Lazzaro, D
    Costa, P
    Poli, V
    Martini, A
    Ciliberto, G
    Fattori, E
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (04) : 643 - 650
  • [5] Gang N, 1999, J RHEUMATOL, V26, P890
  • [6] GEDALIA A, 1992, J RHEUMATOL, V19, P1
  • [7] GRYBOSKI JD, 1978, GASTROENTEROLOGY, V74, P807
  • [8] GH improves growth and clinical status in children with cystic fibrosis - a review of published studies
    Hardin, DS
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2004, 151 : S81 - S85
  • [9] Karlberg P., 1976, ACTA PAEDIATR SC S, V258, P7
  • [10] Kiraz S, 1998, CLIN EXP RHEUMATOL, V16, P721